Inhibrx Biosciences, Inc. · NASDAQ:INBX

Inhibrx Biosciences — Investor Presentation (June 2026)

27 slides from Inhibrx Biosciences's investor presentation, June 2026

  1. Slide 1: Inhibrx Investor Presentation

    INHIBRX Investor Presentation Innovation Driven Outcomes Focused

  2. Slide 2: Presentation disclaimer

    Presentation disclaimer This presentation of Inhibrx Biosciences, Inc. (the “Company”) contains forward-looking 10-Q, and supplemented from time to time by our Current Reports on Form 8-K. The Company statements. In some cases, you can identify forward-looking statements by the words “will,” may not

  3. Slide 3: Our mission: discover and develop effective biologic treatments

    Our mission: To discover & develop effective biologic treatments for people with life-threatening conditions Key financial highlights: (as of 3/31/2026) >300 ozekibart (INBRX-109) $161.7M ~110 Patients treated to date Cash and cash employees with Biosciences equivalents an experienced >175 leadershi

  4. Slide 4: Near Term Expected Milestones

    Near Term Expected Milestones Ozekibart (INBRX-109) INBRX-106 Ozekibart INBRX-106 INBRX-106 Potential first (INBRX-109) PFS data for commercial launch of Interim ORR data for randomized, first line ozekibart for the Phase 3 Ozekibart BLA randomized, HNSCC treatment of portion of submission for the f

  5. Slide 5: INBRX-106

    INBRX-106 Boosting PD-1 efficacy through next-generation hexavalent OX40 agonism

  6. Slide 6: OX40 agonism enhances anti-tumor T cell activity in combo with PD-1 blockade

    OX40 agonism enhances anti-tumor T cell activity in combo with PD-1 INBRX-106 blockade Optimized T cell activation by OX40 agonism and PD-1 blockade T-cell activation critical steps: The ignition The accelerator The brake Signal 1: TCR Signal 2: OX40 T-cell Check point tumor antigen co-stimulation i

  7. Slide 7: INBRX-106 is a hexavalent agonist designed to maximize OX40 signaling

    INBRX-106 is a hexavalent agonist designed to maximize OX40 signaling to INBRX-106 drive antitumor activity Hexavalent OX40 Agonist OX40 High-order OX40 clustering by INBRX-106 JITC Providence Publication Document with solid fill INBRX-106 Advantages of INBRX-106 format GFP AF647 detection Overlay H

  8. Slide 8: Seamless Phase 2/3 study in 1L R/M HNSCC with PD-L1 CPS ≥20

    Seamless Phase 2/3 study in 1L R/M HNSCC with PD-L1 CPS ≥20 INBRX-106 INBRX-106 with pembrolizumab: costimulatory proof of concept study Interim Phase 2 Readout: May 2026 Phase 2, Phase 3, Survival Randomization Open label Double blind Follow-up will be stratified by: + Disease status (locoregional

  9. Slide 9: Interim HexAgon Phase 2 data in 1L HNSCC

    Interim HexAgon Phase 2 data in 1L HNSCC demonstrate INBRX-106 INBRX-106 Potential costimulatory benefit over PD-1 monotherapy Improvement in cORR with Pharmacodynamic evidence of Manageable safety profile superior depth of response potent T-Cell co-activation consistent with immunotherapy combinati

  10. Slide 10: Interim phase 2 data in HNSCC: INBRX-106 + Pembro vs. Pembro

    Interim phase 2 data in HNSCC: INBRX-106 + Pembro vs. Pembro INBRX-106 INBRX-106 + Pembrolizumab Pembrolizumab PD PD Change from Baseline, % * * * * PR * PR * * * * * * * * * 44.0% 21.4% * * SD at 1st scan and PR 2nd scan ongoing not yet confirmed * cORR cORR PR 1st scan and PD at 2nd scan * * * * *

  11. Slide 11: INBRX-106 + pembro drives T-cell proliferation and activation

    INBRX-106 + pembro drives up to 15-fold change in proliferation and up to INBRX-106 4-fold change in activation of T-cells HexAgon Phase 2 – 1L HNSCC Proliferation Activation CD4+ T cells ▪ INBRX-106 is the key driver of T- cell activity in the combination group ▪ INBRX-106 drives up to 15-fold chan

  12. Slide 12: Broad Expandability: development plan in NSCLC, H&N and beyond

    Broad Expandability: development plan to unlock opportunities in NSCLC, INBRX-106 H&N and beyond H&N1 Curative NSCLC 1L Adv/Met Liver Kidney Breast PD-1 Sensitive Bladder Indications 12

  13. Slide 13: Inhibrx path to oncology market leadership

    Inhibrx path to oncology market leadership INBRX-106 Demonstrate INBRX-106 Pursue significant market Expand INBRX-106 to Contribution of Benefit via value in NSCLC wherever PD-1s are Head & Neck Three studies: pembro+106 in 1L TPS > 50% Effective 70 Randomize INBRX-106+pembro vs. (chemo-free); 1L co

  14. Slide 14: Phase 1 data: PD-L1+ CPI-R/R NSCLC

    Phase 1 data: PD-L1+ CPI-R/R NSCLC INBRX-106 INBRX-106 with pembrolizumab 60 40 20 PD Change from baseline, % 0 -20 PR -40 -60 -80 -100 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 19 19 20 21 22 23 24 25 26 PD-L1 TPS 60 20 95 10 80 80 90 2 11 20 3 75 10 10 35 1 50 1 1 10 41 100 50 60 100 90 + The NSCL

  15. Slide 15: Phase 1 data: PD-L1+ CPI-R/R or CPI-naive HNSCC

    Phase 1 data: PD-L1+ CPI-R/R or CPI-naive HNSCC INBRX-106 INBRX-106 with pembrolizumab 60 Cohort CPI-naïve (F4) 40 CPI-R/R (F1) NPC* patient (D2) PD 20 Best change from baseline, % 0 -20 PR -40 -60 -80 -100 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 PD-L1 CPS 0 100 0 30 1 10 75 20 100 100 10 5 24 90 25 + T

  16. Slide 16: ozekibart (INBRX-109)

    ozekibart (INBRX-109) Selectively inducing apoptosis in tumor cells through tetravalent DR5 agonism

  17. Slide 17: Ozekibart registrational trial results: unprecedented data in chondrosarcoma

    Ozekibart (INBRX-109) registrational trial results INBRX-109 Unprecedented data in chondrosarcoma 52% reduction in Median PFS more Improved disease Regulatory progression or death than doubled control rate momentum HR 0.479; 5.52 months 54% vs 27.5% Orphan designations (FDA & EMA) P < 0.0001 vs 2.66

  18. Slide 18: Primary endpoint: progression-free survival by CIRR

    Primary endpoint: progression-free survival by CIRR INBRX-109 3 months 6 months 12 months Ozekibart Placebo 1.0 N=137 N=69 70.1% 0.8 Probability of PFS Events 94 (68.6) 55 (79.7) 47.2% 0.6 / Censored, n (%) / 43 (31.4) / 14 (20.3) 0.4 21.7% 40.9% mPFS, 0.2 months 5.52 2.66 16.9% Ozekibart 9.7% Place

  19. Slide 19: Progression-free survival by CIRR: subgroup analyses

    Progression-free survival by CIRR: subgroup analyses INBRX-109 favors Ozekibart Ozekibart Placebo 0 1 2 3 Events, n/Na mPFS, mo Events, n/Na mPFS, mo HR (95% CI) IDH mutation Wild type 65/93 5.5 38/47 2.7 0.493 (0.324-0.750) status Mutant 29/44 5.5 17/22 2.3 0.442 (0.224-0.871) Prior Yes 38/58 5.3 2

  20. Slide 20: Overall safety data

    Overall safety data INBRX-109 Double-blind period Ozekibart Placebo N=136 N=67 Patients with ≥1 AE (including unrelated AEs), n (%) 129 (94.9) 62 (92.5) Grade ≥3 53 (39.0) 17 (25.4) SAE 38 (27.9) 12 (17.9) HAE 21 (15.4) 9 (13.4) Resulting in death 5 (3.7) 1 (1.5) Patients with ≥1 treatment-related A

  21. Slide 21: Phase 1/2 colorectal adenocarcinoma in combination with FOLFIRI

    Phase 1/2 colorectal adenocarcinoma in combination with FOLFIRI INBRX-109 45 patients evaluable for response: CRC 3-4L with FOLFIRI + ~70% are 4th line & ~30% are 3rd line Key inclusion N=50 + ~80% have received prior IRI-containing criteria regiment • LA/M, unresectable, R/R colorectal Ozekibart 3

  22. Slide 22: Phase 1/2 colorectal adenocarcinoma in combination with FOLFIRI

    Phase 1/2 colorectal adenocarcinoma in combination with FOLFIRI INBRX-109 CR PR SD PR SD PR SD SD SD SD PR SD SD SD SD Individual patient time SD PR on treatment shows SD SD sustained disease SD SD control in heavily pre- SD PR SD treated patients PR SD SD SD SD SD Prior Treatment Status: SD SD 2 li

  23. Slide 23: Phase 1/2 colorectal adenocarcinoma: change from baseline

    Phase 1/2 colorectal adenocarcinoma in combination with FOLFIRI INBRX-109 40 32 26 25 22 20 17 PDa 11 Benchmarks ORR (%) 5 5 Lonsurf + bev 0 (SUNLIGHT, 6.1 -3 -3 -3 -3 -4 -6 -7 2023) -10 -11 Change from Baseline, % regorafenib -14 -15 -16 -16 -17 1.0 -20 (CORRECT, 2013) -21 -21 -22 -23 PRb -25 fruqu

  24. Slide 24: Ongoing phase 1/2 trial in Ewing sarcoma with IRI/TMZ

    Ongoing phase 1/2 trial in Ewing sarcoma in combination with IRI/TMZ INBRX-109 EWS 2-3L with IRI/TMZ Key inclusion N=50 criteria Ozekibart 3 mg/kg + IRI 50 • LA/M, unresectable, R/R EWS mg/m2/day + • Aged ≥12 to <85 years TMZ 100 mg/m2/day • EWSR1-FLI1, -ERG or -FEV rearrangement • 1-2 prior lines o

  25. Slide 25: Updated data from expansion cohort: Ewing sarcoma

    Updated data from expansion cohort: Ewing sarcoma in combination INBRX-109 with IRI/TMZ 100 Recruitment ongoing 80 39 patients dosed with 31 patients currently evaluable for response: 60 Prior IRI/TMZ Treatment Change from baseline, % No N=31 40 Yes Progressive disease 20 Disease control rate was 87

  26. Slide 26: Ozekibart exhibits anti-tumor activity in GBM models

    Ozekibart exhibits anti-tumor activity in GBM models INBRX-109 as monotherapy and in combination with TMZ Human GBM cell line models In vitro cytotoxicity In vitro cytotoxicity Intracranial U-87 MG Intracranial U-87 MG + Combination treatment with ozekibart U-87 MG GBM cell lines Survival analysis S

  27. Slide 27: Investor Relations

    Investor Relations: KELLY DECK, CPA CFO 11025 N. Torrey Pines Road Suite 140 La Jolla, CA 92037 858.795.4260 ir@inhibrx.com

Inhibrx Biosciences — Investor Presentation (June 2026) on 6ix